Zomato co-founder Deepinder Goyal has begun rolling out the first 100 units of his experimental wearable, Temple, marking a shift from private prototype to early user testing.
Positioned on the temple region, the device is designed to capture physiological signals that its creators believe could offer insights into human performance, recovery, and long-term health patterns.
Goyal has also linked the broader vision behind the device to an exploratory “anti-ageing” hypothesis, suggesting that understanding subtle changes in circulation and physiology may help decode ageing processes. While still in its early stage, the rollout signals a new phase of real-world experimentation and feedback.
Deepinder Goyal’s Temple Device
Zomato co-founder Deepinder Goyal has unveiled the first 100 Temple devices and is actively inviting early users into the ecosystem. The move signals a closed beta phase where select users will test the wearable before any broader availability.
“The first 100 Temples are ready to ship. We’re now inviting athletes, scientists, founders, doctors, creators, and individuals who care deeply about their physical and cognitive health to be the founding users of Temple,” Goyal wrote in his social media post.
While the company continues to frame Temple as experimental, the introduction of real users changes the context significantly. A prototype worn by its creator is one thing. A device being tested by external users, even in a limited group, introduces questions of data handling, interpretation, and responsibility.
This is the moment where experimentation begins to intersect with expectation.
What Is The Temple Device
The Temple device is an experimental wearable developed under Deepinder Goyal’s private research initiative, designed to sit near the temple and track cerebral blood flow in real time. Reports describe it as a non-invasive sensor aimed at observing how blood circulation to the brain changes with posture, activity, and stress states.
Temple’s website describes it as “Temple is a precision instrument, built to get the most out of your training, recovery, work, and sleep. It’s worn on the temple, where thin tissue, highly vascularized fascia, the superficial temporal artery, and dense autonomic regulation of skin blood flow create a cleaner, richer signal and a deeper window into human physiology.”
Goyal’s Gravity Ageing Hypothesis
What makes Temple particularly distinct from conventional wearables is not just its form factor, but the conceptual framework behind it.
Deepinder Goyal has publicly referenced what he calls the “Gravity Ageing Hypothesis,” which suggests that long-term gravitational effects on blood circulation could subtly influence ageing processes by affecting how efficiently blood reaches the brain over time.
The medical community, however, views this as an unverified hypothesis rather than an established biological mechanism. Experts have pointed out that ageing is understood as a multi-factor process involving genetics, environment, metabolic changes, and disease pathways, rather than a single mechanical factor like gravity-driven perfusion decline.
Importantly, Goyal himself has indicated that the usefulness of the device may not depend entirely on whether this hypothesis is correct. In other words, even if the gravity-based framing does not hold in its current form, the underlying data on physiological patterns could still have exploratory value.
That positioning places Temple in a category closer to research instrumentation than finished medical product.
From Curiosity To Controlled Access
The “Temple” device first entered public consciousness not through a product launch, but through speculation. A small metallic sensor worn near the temple during a podcast appearance triggered widespread online curiosity, with users and even doctors debating what it actually did.
According to multiple reports, the device is described as an experimental wearable designed to monitor cerebral blood flow and related physiological signals in real time.
Goyal has consistently framed it as a prototype rather than a commercial product, clarifying that it is still under development and has not undergone full scientific validation or regulatory testing.
The recent move to open access to early users, reportedly in a limited rollout, marks a shift from private experimentation to semi-public deployment.
The Logical Indian’s Perspective
Innovation like Temple reflects how far India’s startup ecosystem is willing to push the boundaries of human-centered technology, especially in understanding physiology and performance. Exploring new ways to interpret biological signals is both exciting and necessary for progress.
At the same time, ideas that move closer to brain and health data must be supported by stronger clinical validation and peer-reviewed research. Encouraging experimentation while demanding scientific rigor is not resistance to innovation, but what ensures it becomes meaningful and trustworthy over time.
Also Read: $16.4 Billion And 70,800 Jobs: How Indian Companies Are Expanding America’s Workforce
